Rhumbline Advisers Harrow Health, Inc. Transaction History
Rhumbline Advisers
- $109 Billion
- Q3 2024
A detailed history of Rhumbline Advisers transactions in Harrow Health, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 41,027 shares of HROW stock, worth $1.39 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
41,027
Previous 43,021
4.63%
Holding current value
$1.39 Million
Previous $898,000
105.35%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding HROW
# of Institutions
176Shares Held
21.4MCall Options Held
845KPut Options Held
717K-
Opaleye Management Inc. Boston, MA3.99MShares$135 Million32.75% of portfolio
-
Private Capital Management, LLC Naples, FL2.16MShares$73.2 Million11.41% of portfolio
-
Black Rock Inc. New York, NY2.15MShares$72.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.87MShares$63.2 Million0.0% of portfolio
-
State Street Corp Boston, MA731KShares$24.7 Million0.0% of portfolio
About HARROW HEALTH, INC.
- Ticker HROW
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 27,070,000
- Market Cap $916M
- Description
- Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company tha...